AtriCure Inc. shares reached a 52-week high of $50 on Monday, extending a rally that has delivered a 40.7% gain over the past 12 months.
The stock's advance follows second-quarter 2026 results that exceeded expectations. Adjusted earnings came in at $0.18 per share, compared with an anticipated loss of $0.01. Revenue totaled $153.6 million, surpassing the forecast of $151.84 million.
Analysts at Needham, Piper Sandler and BTIG raised their price targets on the medical device maker. Needham set a new target of $64, maintaining a Buy rating. Piper Sandler increased its target to $60, while BTIG raised its target to $55. The stock has gained nearly 24% year-to-date and 58% over the past six months.
The upgrades reflect growing confidence in AtriCure's cardiac ablation portfolio, particularly its BoxX-NoAF randomized controlled trial and a new quality measure introduced by the Society of Thoracic Surgeons. The measure is expected to benefit the company's open ablation business and the adoption of its Open Ablation products.
InvestingPro analysis noted that AtriCure's stock appeared overvalued relative to its Fair Value, with the Relative Strength Index indicating overbought conditions. Despite the strong quarterly results, investor caution persists regarding the outlook for the remainder of the year.
